Skip to main content
Top
Published in: Respiratory Research 1/2018

Open Access 01-12-2018 | Research

Immunohistological features related to functional impairment in lymphangioleiomyomatosis

Authors: Ellen Caroline Toledo do Nascimento, Bruno Guedes Baldi, Alessandro Wasum Mariani, Raquel Annoni, Ronaldo Adib Kairalla, Suzana Pinheiro Pimenta, Luiz Fernando Ferraz da Silva, Carlos Roberto Ribeiro Carvalho, Marisa Dolhnikoff

Published in: Respiratory Research | Issue 1/2018

Login to get access

Abstract

Background

Lymphangioleiomyomatosis (LAM) is a low-grade neoplasm characterized by the pulmonary infiltration of smooth muscle-like cells (LAM cells) and cystic destruction. Patients usually present with airway obstruction in pulmonary function tests (PFTs). Previous studies have shown correlations among histological parameters, lung function abnormalities and prognosis in LAM. We investigated the lung tissue expression of proteins related to the mTOR pathway, angiogenesis and enzymatic activity and its correlation with functional parameters in LAM patients.

Methods

We analyzed morphological and functional parameters of thirty-three patients. Two groups of disease severity were identified according to FEV1 values. Lung tissue from open biopsies or lung transplants was immunostained for SMA, HMB-45, mTOR, VEGF-D, MMP-9 and D2-40. Density of cysts, density of nodules and protein expression were measured by image analysis and correlated with PFT parameters.

Results

There was no difference in the expression of D2-40 between the more severe and the less severe groups. All other immunohistological parameters showed significantly higher values in the more severe group (p ≤ 0.002). The expression of VEGF-D, MMP-9 and mTOR in LAM cells was associated with the density of both cysts and nodules. The density of cysts and nodules as well as the expression of MMP-9 and VEGF-D were associated with the impairment of PFT parameters.

Conclusions

Severe LAM represents an active phase of the disease with high expression of VEGF-D, mTOR, and MMP-9, as well as LAM cell infiltration. Our findings suggest that the tissue expression levels of VEGF-D and MMP-9 are important parameters associated with the loss of pulmonary function and could be considered as potential severity markers in open lung biopsies of LAM patients.
Literature
1.
go back to reference Travis WD, Brambilla E, Nicholson AG, et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–60.CrossRefPubMed Travis WD, Brambilla E, Nicholson AG, et al. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–60.CrossRefPubMed
2.
go back to reference Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO classification of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon, FR: IARC; 2015. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO classification of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon, FR: IARC; 2015.
3.
go back to reference McCormack FX, Travis WD, Colby TV, et al. Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med. 2012;186(12):1210–2.CrossRefPubMedPubMedCentral McCormack FX, Travis WD, Colby TV, et al. Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med. 2012;186(12):1210–2.CrossRefPubMedPubMedCentral
4.
go back to reference Hohman DW, Noghrehkar D, Ratnayake S. Lymphangioleiomyomatosis: a review. Eur J Intern Med. 2008;19(5):319–24.CrossRefPubMed Hohman DW, Noghrehkar D, Ratnayake S. Lymphangioleiomyomatosis: a review. Eur J Intern Med. 2008;19(5):319–24.CrossRefPubMed
5.
go back to reference Baldi BG, Freitas CS, Araujo MS, et al. Clinical course and characterization of lymphangioleiomyomatosis in a brazilian reference centre. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):129–35.PubMed Baldi BG, Freitas CS, Araujo MS, et al. Clinical course and characterization of lymphangioleiomyomatosis in a brazilian reference centre. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31(2):129–35.PubMed
6.
go back to reference Johnson SR, Cordier JF, Lazor R, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010;35(1):14–26.CrossRefPubMed Johnson SR, Cordier JF, Lazor R, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010;35(1):14–26.CrossRefPubMed
7.
go back to reference Matsui K, Beasley MB, Nelson WK, et al. Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Pathol. 2001;25(4):479–84.CrossRefPubMed Matsui K, Beasley MB, Nelson WK, et al. Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Pathol. 2001;25(4):479–84.CrossRefPubMed
8.
go back to reference Goncharova EA, Krymskaya VP. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges. J Cell Biochem. 2008;103(2):369–82.CrossRefPubMed Goncharova EA, Krymskaya VP. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges. J Cell Biochem. 2008;103(2):369–82.CrossRefPubMed
10.
go back to reference Matsui K, Takeda k, Yu ZX, et al. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med. 2000;124(2):267–75.PubMed Matsui K, Takeda k, Yu ZX, et al. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med. 2000;124(2):267–75.PubMed
11.
go back to reference Robb VA, Astrinidis A, Henske EP. Frequent hyperphosphorylation of ribosomal protein S6 in lymphangioleiomyomatosis-associated angiomyolipomas. Mod Pathol. 2006;19(6):839–46.CrossRefPubMed Robb VA, Astrinidis A, Henske EP. Frequent hyperphosphorylation of ribosomal protein S6 in lymphangioleiomyomatosis-associated angiomyolipomas. Mod Pathol. 2006;19(6):839–46.CrossRefPubMed
12.
13.
go back to reference Kitaichi M, Nishimura K, Itoh H, et al. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med. 1995;151(2):527–33.CrossRefPubMed Kitaichi M, Nishimura K, Itoh H, et al. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med. 1995;151(2):527–33.CrossRefPubMed
14.
go back to reference Pereira CA, Sato T, Rodrigues SC. New reference values for forced spirometry in white adults in Brazil. J Bras Pneumol. 2007;33(4):397–406.CrossRefPubMed Pereira CA, Sato T, Rodrigues SC. New reference values for forced spirometry in white adults in Brazil. J Bras Pneumol. 2007;33(4):397–406.CrossRefPubMed
15.
go back to reference Neder JA, Andreoni S, Castelo-Filho A, Nery LE. Reference values for lung function tests. I. Static volumes. Braz J Med Biol Res. 1999;32(6):703–17.CrossRefPubMed Neder JA, Andreoni S, Castelo-Filho A, Nery LE. Reference values for lung function tests. I. Static volumes. Braz J Med Biol Res. 1999;32(6):703–17.CrossRefPubMed
16.
go back to reference Neder JA, Andreoni S, Peres C, et al. Reference values for lung function tests. III. Carbon monoxide diffusing capacity (transfer factor). Braz J Med Biol Res. 1999;32(6):729–37.CrossRefPubMed Neder JA, Andreoni S, Peres C, et al. Reference values for lung function tests. III. Carbon monoxide diffusing capacity (transfer factor). Braz J Med Biol Res. 1999;32(6):729–37.CrossRefPubMed
19.
go back to reference Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis. Am J Surg Pathol. 2004;28(8):1007–16.CrossRefPubMed Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis. Am J Surg Pathol. 2004;28(8):1007–16.CrossRefPubMed
20.
go back to reference Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangileiomyomatosis. Am J Surg Pathol. 2005;29(10):1356–66.CrossRefPubMed Kumasaka T, Seyama K, Mitani K, et al. Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangileiomyomatosis. Am J Surg Pathol. 2005;29(10):1356–66.CrossRefPubMed
22.
go back to reference Taveira-DaSilva AM, Pacheco-Rodriguez G, Moss J. The natural history of lymphangioleiomyomatosis: makers of severity, rate of progression and prognosis. Lymphat Res Biol. 2010;8(1):9–19.CrossRefPubMedPubMedCentral Taveira-DaSilva AM, Pacheco-Rodriguez G, Moss J. The natural history of lymphangioleiomyomatosis: makers of severity, rate of progression and prognosis. Lymphat Res Biol. 2010;8(1):9–19.CrossRefPubMedPubMedCentral
23.
go back to reference Baldi BG, Araujo MS, Freitas CSG, et al. Evaluation of the extent of pulmonary cysts and their association with functional variables and serum markers in lymphangioleiomyomatosis (LAM). Lung. 2014;192(6):967–74.CrossRefPubMed Baldi BG, Araujo MS, Freitas CSG, et al. Evaluation of the extent of pulmonary cysts and their association with functional variables and serum markers in lymphangioleiomyomatosis (LAM). Lung. 2014;192(6):967–74.CrossRefPubMed
24.
go back to reference Yao J, Taveira-DaSilva AM, Colby TV, et al. CT grading of lung disease in lymphamgioleiomyomatosis. AJR Am J Roentgenol. 2012;199(4):787–93.CrossRefPubMed Yao J, Taveira-DaSilva AM, Colby TV, et al. CT grading of lung disease in lymphamgioleiomyomatosis. AJR Am J Roentgenol. 2012;199(4):787–93.CrossRefPubMed
25.
go back to reference Crausman RS, Lynch DA, Mortenson RL, et al. Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangioleiomiomatosis. Chest. 1996;109:131–7.CrossRefPubMed Crausman RS, Lynch DA, Mortenson RL, et al. Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangioleiomiomatosis. Chest. 1996;109:131–7.CrossRefPubMed
26.
go back to reference Odajima N, Betsuyaku T, Yoshida T, et al. High levels of extracellular matrix metalloproteinase inducer are expressed in lymphangioleiomyomatosis. Hum Pathol. 2010;41(7):935–43.CrossRefPubMed Odajima N, Betsuyaku T, Yoshida T, et al. High levels of extracellular matrix metalloproteinase inducer are expressed in lymphangioleiomyomatosis. Hum Pathol. 2010;41(7):935–43.CrossRefPubMed
27.
go back to reference Maa HC, Chao TT, Wang CY, et al. VEGF-D as a marker in the aid of malignant metastatic pleural effusion diagnosis. Appl Immunohistochem Mol Morphol. 2015;23(3):209–14.CrossRefPubMed Maa HC, Chao TT, Wang CY, et al. VEGF-D as a marker in the aid of malignant metastatic pleural effusion diagnosis. Appl Immunohistochem Mol Morphol. 2015;23(3):209–14.CrossRefPubMed
28.
go back to reference Gupta R, Kitaichi M, Inoue Y, et al. Lymphatic manifestations of lymphangioleiomyomatosis. Lymphology. 2014;47(3):106–17.PubMed Gupta R, Kitaichi M, Inoue Y, et al. Lymphatic manifestations of lymphangioleiomyomatosis. Lymphology. 2014;47(3):106–17.PubMed
29.
go back to reference Seyama K, Kumasaka T, Souma S, et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol. 2006;4(3):143–52.CrossRefPubMed Seyama K, Kumasaka T, Souma S, et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol. 2006;4(3):143–52.CrossRefPubMed
31.
go back to reference Young LR, Vandyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest. 2010;138(3):674–81.CrossRefPubMedPubMedCentral Young LR, Vandyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest. 2010;138(3):674–81.CrossRefPubMedPubMedCentral
32.
go back to reference Young L, Lee HS, Inoue Y, et al. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the multicenter international lymphangioleiomyomatosis efficacy of sirolimus (MILES) trial. Lancet Respir Med. 2013;1(6):445–52.CrossRefPubMedPubMedCentral Young L, Lee HS, Inoue Y, et al. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the multicenter international lymphangioleiomyomatosis efficacy of sirolimus (MILES) trial. Lancet Respir Med. 2013;1(6):445–52.CrossRefPubMedPubMedCentral
33.
go back to reference Yu J, Henske EP. mTOR activation, lymphangiogenesis and estrogen-mediated cell survival: the perfect storm of pro-metastatic factors in LAM pathogenesis. Lymphat Res Biol. 2010;8(1):43–9.CrossRefPubMedPubMedCentral Yu J, Henske EP. mTOR activation, lymphangiogenesis and estrogen-mediated cell survival: the perfect storm of pro-metastatic factors in LAM pathogenesis. Lymphat Res Biol. 2010;8(1):43–9.CrossRefPubMedPubMedCentral
34.
go back to reference Xu KF, Zhang P, Tian X, et al. The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM). Respir Med. 2013;107(2):263–8.CrossRefPubMed Xu KF, Zhang P, Tian X, et al. The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM). Respir Med. 2013;107(2):263–8.CrossRefPubMed
35.
go back to reference Yen KT, Putzke JD, Staats BA, et al. The prevalence of acute response to bronchodilator in pulmonary lymphangioleiomyomatosis. Respirology. 2005;10(5):643–8.CrossRefPubMed Yen KT, Putzke JD, Staats BA, et al. The prevalence of acute response to bronchodilator in pulmonary lymphangioleiomyomatosis. Respirology. 2005;10(5):643–8.CrossRefPubMed
36.
37.
go back to reference Taveira Da Silva AM, Steagall WK, Moss J. Lymphangioleiomyomatosis. Cancer Control. 2006;13(4):276–85.CrossRef Taveira Da Silva AM, Steagall WK, Moss J. Lymphangioleiomyomatosis. Cancer Control. 2006;13(4):276–85.CrossRef
Metadata
Title
Immunohistological features related to functional impairment in lymphangioleiomyomatosis
Authors
Ellen Caroline Toledo do Nascimento
Bruno Guedes Baldi
Alessandro Wasum Mariani
Raquel Annoni
Ronaldo Adib Kairalla
Suzana Pinheiro Pimenta
Luiz Fernando Ferraz da Silva
Carlos Roberto Ribeiro Carvalho
Marisa Dolhnikoff
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2018
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-018-0797-9

Other articles of this Issue 1/2018

Respiratory Research 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.